Earnings Scheduled For March 22, 2024
Portfolio Pulse from Benzinga Insights
Earnings reports for March 22, 2024, include several companies across various sectors. Notable mentions are Agile Therapeutics, 51 Talk Online Education, Star Equity Holdings, Hyzon Motors, Humacyte, AstroNova, Sunlands Technology, and Moleculin Biotech. These companies are expected to report their quarterly earnings, with some projecting losses.
March 22, 2024 | 9:40 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
AstroNova is likely to report earnings for its fourth quarter.
Without specific earnings figures, the impact on the stock price is uncertain, but the earnings report could draw investor attention.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
NEUTRAL IMPACT
51 Talk Online Education is projected to report earnings for its fourth quarter.
Without specific earnings projections, the impact on the stock price is uncertain, but investor interest may increase around the earnings report.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
NEUTRAL IMPACT
Hyzon Motors is likely to report earnings for its fourth quarter.
The absence of specific earnings projections makes the potential impact on the stock price uncertain, though it could generate investor interest.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
NEUTRAL IMPACT
Moleculin Biotech is estimated to report earnings for its fourth quarter.
Without specific projections, the impact on the stock price is uncertain, but the earnings report could influence investor sentiment.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
NEUTRAL IMPACT
Sunlands Technology is likely to report earnings for its fourth quarter.
The lack of detailed earnings projections leaves the potential impact on the stock price uncertain, though it may increase investor interest.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
Agile Therapeutics is expected to report a quarterly loss of $0.54 per share on revenue of $9.20 million.
Projected losses typically lead to negative investor sentiment in the short term, potentially impacting the stock price negatively.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
Humacyte is estimated to report a quarterly loss of $0.24 per share on revenue of $60 thousand.
Projected significant losses on minimal revenue are likely to negatively affect investor sentiment and the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
Star Equity Holdings is likely to report a quarterly loss of $0.08 per share on revenue of $9.15 million.
Anticipated losses can lead to a negative perception among investors, potentially driving the stock price down in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90